Firefly Neuroscience (AIFF) announced advancing its artificial intelligence-powered Brain Network Analytics technology after successful research collaborations with Takeda Pharmaceutical (TAK) and Novartis (NVS), two global leaders in pharmaceutical R&D, illustrating the value of Firefly’s AI-based technology in providing objective measures in neuroscience drug development. “Our collaborations with Takeda and Novartis mark a pivotal step in accelerating drug development,” said Jon Olsen, Firefly’s CEO. “By using our BNA(TM) technology, pharmaceutical companies can leverage the additional objective measures of brain activity to enhance the design of future trials and advance their drug candidates faster toward regulatory approval.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AIFF:
- Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
- Firefly Neuroscience enters partnership with Zeto
- Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto’s FDA-Cleared EEG Device Platform
- Firefly Neuroscience appoints Stella Vnook to board of directors
- Firefly Neuroscience Appoints Dr. Stella Vnook to its Board of Directors